CCM
APRE icon

CAAS Capital Management’s Aprea Therapeutics APRE Stock Holding History

CAAS Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,204
Closed -$906K – 1141
2020
Q4 		$906K Buy
+9,204
New +$4.38M 0.01% 624
2020
Q3 		– Sell
-303
Closed -$235K – 473
2020
Q2 		$235K Buy
+303
New +$199K 0.01% 360

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CAAS Capital Management's APRE Position: Q1 2021 in Review

CAAS Capital Management sold out of Aprea Therapeutics (APRE) in Q1 2021, closing a stake of 9,204 shares — an estimated $906K sold.

CAAS Capital Management first reported a position in APRE in Q2 2020 and held it in 2 quarters. The position peaked at $906K in Q4 2020. 67 funds tracked by Wall St. Rank hold APRE as of Q1 2021.

  • CAAS Capital Management reported no remaining Aprea Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 9,204 Aprea Therapeutics shares in Q1 2021, an estimated $906K.
  • CAAS Capital Management first reported a position in Aprea Therapeutics in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Aprea Therapeutics position peaked at $906K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.